Internationally, Dexcom has seen pockets of strength in key markets, such as Japan and France, where recent type 2 diabetes ...

In April 2025, DexCom received approval for its G7 15-Day CGM system, a development that was anticipated based on previous management comments. While this approval is not expected to significantly ...

Dexcom reaffirmed its 2025 revenue guidance of ... with evident confidence in key initiatives like the 15-day G7 launch. Revenue growth accelerated to 14% in Q1 2025 from 8% in Q4 2024.

May 27, 2025) - American Diversified Holdings Corporation (OTC Pink: ADHC) announced today that GlucoGuard has completed the ...

In the first quarter, Dexcom’s G7 system continued its robust momentum. Accelerated conversion of the installed base for G7 manufacturing is driving strong revenue performance and improving ...

In earnings calls, diabetes tech companies had less to say about tariffs and focused more on future growth.

What Makes Stelo – and OTC CGMs – Different Traditional prescription CGMs like the Dexcom G7 are designed for people with diabetes, offering tight integration with insulin pumps, customizable ...

Dexcom launched the Stelo over-the-counter CGM and announced that the 15-day G7 system, cleared by the FDA, will be launched in the second half of 2025. The new system is expected to offer ...